Pritesh Shah

Chief Commercial OfficeratNovoCure· In proxies 2021–2023

Pay in FY2023-18% from the year before · NovoCure stock -79.6% the same year

Pritesh Shah was paid $5.2M in FY2023 (Dec), down 18%. NovoCure stock fell 79.6% that year.

Pay$100 in the stock at the end of FY20 → $9

Pay is from the Summary Compensation Table of each NovoCure proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

NVCR
NovoCurePublic company · 5 yr
- Chief Commercial Officer2021 – Present · 5 yrStock in role -92%

Roles come from the proxy statements of each company.

Activity

Pay
NovoCure Division head pay fell 18% to $5.2M. The stock fell 80% in FY2023 (Dec).
DEF 14AApr 22, 2024
Pay
NovoCure Division head pay rose 15% to $6.3M. The stock fell 2% in FY2022 (Dec).
DEF 14AApr 22, 2024

For the press:Download CSV Download PNG How to use our data

Two people shown as one, or a wrong number?